Overview

Abatacept Pregnancy Exposure Registry

Status:
Unknown status
Trial end date:
2019-12-31
Target enrollment:
Participant gender:
Summary
The purpose of the abatacept pregnancy registry is to monitor planned and unplanned pregnancies exposed to abatacept, to evaluate the possible teratogenic effects (that is, any abnormal development) of this medication in the pregnancy outcome and to follow live born infants for one year after birth.
Details
Lead Sponsor:
Bristol-Myers Squibb
Collaborators:
The Organization of Teratology Information Specialists
University of California, San Diego
Treatments:
Abatacept